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1. Introduction 
Hodgkin lymphoma (HL), formerly called Hodgkin’s disease, is a malignancy of mature B-
cell lineage (germinal or post-germinal center), with over 8,000 new cases diagnosed 
annually in the United States.[1] HL has historically been characterized by many histologic 
subtypes with the finding of Reed-Sternberg cells unify the diagnosis. HL is well known to 
have a bimodal distribution of incidence, occurring most frequently in two distinct age 
groups: young adults (age 15-35) and those ages greater than 55 years old. For the purpose 
of this chapter, we will focus on the young adults treated for and cured of HL with radiation 
therapy (RT), chemotherapy, or combined modality therapy (CMT). 
HL remains in many ways the archetype within oncology with regards to incremental 
improvements, established through well-performed clinical trials, turning an incurable and 
universally fatal illness into one that is, more often than not, cured with first-line therapy. 
The need for an understanding of how best to care for survivors of HL is predicated upon 
patients being cured of their HL. This was first achieved in the 1960’s when HL was shown 
to be a curable disease, first with high-dose extended field RT,[2] and subsequently with 
multi-agent chemotherapeutic regimens such as MOPP (nitrogen mustard, vincristine, 
procarbazine, and prednisone).[3] Increasingly intensive treatments, however, were 
handcuffed to increasing toxicity.[4] As the likelihood of cure started to plateau in the 1990’s 
at approximately 80%, the toxic consequences of these intensified treatment regimens – 
acute as well as late effects – increasingly came into focus.[5] As HL is largely a disease of 
young, functional, and fertile, with survivors often living long lives (with whatever 
impairment resulting from disease and treatment), the need to better understand the 
medical needs of survivors of HL began to receive significant attention from the medical 
community. Additionally, investigators began to pursue improvement in HL therapy from a 
very different perspective – seeking not to identify further intensifications of therapy, but 
rather to attempt to delineate how treatment toxicities could be limited without sacrificing 
the excellent outcomes gained over the past decades. Accordingly, improvements in 
radiation delivery have led to preferential use of smaller fields (involved field radiation 
therapy, and now even involved nodal field radiation in select circumstances.[6, 7] Efforts in 
the development of systemic chemotherapy for HL have been focused upon not only 
www.intechopen.com
 
Hodgkin's Lymphoma 256 
intensification of therapy, but in the selective application of such treatment. Currently, the 
management of HL is driven by patient- and disease-specific characteristic including age 
and gender, stage, bulk, location, and risk models specific for early or advanced stage 
disease.[8-12] Early-stage patients, particularly those with bulky disease (most often defined 
as a mass greater than 10 cm in long-axis diameter or encompassing more than a third of the 
intrathoracic diameter) are commonly treated with combined modality approaches of 
varying intensity.[13] Advanced disease is frequently treated with chemotherapy alone with 
consolidation radiation therapy to sites of bulk [14], although here, intensity of treatment is 
often dictated by risk prediction. The next generation of clinical trials seeks more 
individualized and specific ways to tailor treatment intensity, particularly using response-
adapted strategies with early restaging functional imaging with 18-fluorodeoxyglucose 
(FDG) positron emission tomography (PET). As treatments continue to emerge, and evolve, 
the needs of survivors will of course develop in kind. Nonetheless, there exist over 160,000 
patients living after being cured of HL; having received treatments with long-term effects, 
and it is the optimal care of these patients that is the focus of survivorship efforts.[15]  
2. Importance of post-treatment care 
During the first 10 years following diagnosis of HL, relapse remains the leading cause of 
death. [16] However, by 15-20 years following diagnosis, risk of death due to causes other 
than HL will have surpassed those due to the lymphoma itself.[17, 18]  By risk stratification, 
those with early stage disease are more likely to have secondary malignancy and 
cardiovascular disease when compared to those with advance disease, an observation 
attributable to improved prognosis as well as effects from RT, more often a component of 
therapy for early stage disease. As the risk of relapse diminishes after treatment the 
subsequent quality of life altering comorbidities become apparent and accelerated.[19] 
Although second primary malignancy and cardiovascular disease are the most frequent 
causes of non-lymphoma mortality among patients with HL, they are far from the only 
medical conditions for which they are at risk. Pulmonary, musculoskeletal, endocrine, 
neurologic, and psychiatric illness all occur at increased frequency among HL survivors, 
typically as direct sequelae of the disease or its treatment. Tellingly, a single-institution 
series investigating the global effects of late morbidity found that, among survivors an 
average of 21 years post-treatment, 94% reported at least one morbidity of any grade 
severity, 50% at least one morbidity of grade 3 or greater (according to a modification of the 
Common Terminology Criteria for Adverse Events, version 3), and 23% two or more 
morbidities of grade 3 or greater.[18] In order for a physician to offer optimal care for 
survivors of HL, such care should be built upon an understanding of these risks, both 
individually and collectively.[20] 
3. Second primary malignancy 
Unfortunately, among those cured of HL, second primary malignancy remains the leading 
cause of mortality 15 years after disease-free survival.[21] For instance, a risk model 
approximated that those diagnosed at the age of 30 with HL will have a 30 year cumulative 
risk of second primary malignancy for men and women at 18% and 26%, respectively, 
compared to age-matched risks of 7% and 9%.[22, 23]  The latency of the various second 
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malignancies seen following therapy for HL varies by histology. Risk for myelodysplastic 
syndrome (MDS) and acute myelogenous leukemia (AML) peak at three to five years after 
therapy and return to population baseline, or at most remain minimally elevated, by 10 
years after.[24-26] The inverse is true for solid tumor malignancies, where increased risk 
only first becoming appreciable by 10 years after the completion of therapy.[27] 
4. Hematologic malignancies 
Already survivors of one hematologic malignancy, the fact that they are at heightened risk 
for the development of additional hematologic malignancies – particularly MDS, AML, and 
non-Hodgkin lymphoma (NHL) – are a source of frustration to doctors and patients alike. 
Treatment-induced MDS or AML is a well-established risk of HL therapy; the relative risk of 
acute leukemia among patients cured of HL is 80 times greater than the general population, 
although the absolute excess risk is low.[28] The risk of MDS/AML is largely predicated 
upon the treatment delivered, as the cumulative dose of potent alkylating chemotherapy 
(e.g., mechlorethamine) or topoisomerase inhibitors (e.g., doxorubicin or etoposide) and the 
delivery of radiotherapy account for much of this increased risk.[24, 29] Despite ongoing 
advancements in the treatment of the acute leukemias, treatment-related AML remains 
profoundly dangerous, with median survival measured in months.[28] Indeed, it was in part 
the leukemogenicity of the older MOPP regimen that helped fuel the ascendance of ABVD 
(doxorubicin, bleomycin, vinblastine, and dacarbazine) as the chemotherapeutic standard of 
care for average-risk HL. The absolute excess risk of AML following treatment with ABVD 
is between 0 and 0.4%, whereas with MOPP was 2.8% (and with MOPP and radiotherapy as 
CMT, 5.5%).[25, 30, 31] The modern intensified regimen, escalated BEACOPP (bleomycin, 
etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone), and 
is associated with a risk of AML of 3.2%. This observation has largely led to the selective use 
of this highly effective regimen only in high-risk patients – patients in whom the risk of poor 
outcomes with ABVD merit exposure to more leukemogenic therapy.[32] The risk of 
secondary acute leukemia in patients receiving consolidative RT for HL appears to be more 
closely related to the field of therapy than to the delivered dose.[27] This contribution to 
leukemia risk has been somewhat mitigated, as modern RT strives to limit therapeutic 
exposure, preferring involved fields to extended fields, although these efforts are not 
expected to entirely obviate the contribution to risk of leukemia from radiotherapy.  
In addition to acute myelogenous leukemia, HL survivors are also at increased risk for the 
subsequent development of non-Hodgkin lymphoma (NHL).[21, 33, 34] The risk appears to 
be influenced by the selection of treatment, with alkylator therapy and radiotherapy 
emerging as the likely causes of oncogenesis. Estimates of the relative risk of NHL among 
survivors of HL are varied across reports, ranging from 2 to 22, but the absolute risks are 
low: The 25-year cumulative risk of NHL is less than 4%, and the absolute excess risk (AER) 
of NHL is less than 10 cases per 10,000 person-years.[21]  
5. Solid tumor malignancies 
Although the development of a second primary hematologic neoplasms following curative 
treatment for HL is a potentially life-threatening event, and one for which survivors are at 
far greater risk than age-matched controls, solid tumors collectively comprise a much 
greater risk for survivors – 75% of second primary malignancies will not be AML or NHL, 
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but rather will be of solid organ origin, and unlike the risk of AML, the risk (and excess risk) 
of solid organ malignancy has no apparent plateau among HL survivors. Unlike AML, 
however, much of the risk of solid tumors arising from treatment of HL is attributable to 
local genotoxic damage due to radiation therapy; each routine involved field of 
radiotherapy is associated with potential solid-tumor risks within the given field (Figure 1). 
 
 
 
Reprinted with permission from: Stubblefield MD. Radiation fibrosis syndrome: neuromuscular and 
musculoskeletal complications in cancer survivors. PM&R 2011;3:1041-54. 
Fig. 1. Radiation therapy fields in the treatment of classical Hodgkin lymphoma. 
www.intechopen.com
 
Survivorship in Hodgkin Lymphoma 259 
6. Lung cancer  
HL survivors are at increased risk for developing lung cancer; with a relative risk of 7 and 
an AER of 7 per 10,000 person-years, lung cancer represents a serious cause of morbidity 
and mortality.[22, 35-39]  This risk is mediated by the volume and dose of lung tissue 
exposure to ionizing radiation, cumulative dose of alkylating chemotherapy, and 
environmental factors.[22] HL patients who had a positive smoking history and received 
radiation therapy as a part of their management have a markedly higher incidence of lung 
cancer when compared to HL who non-smokers and received radiation therapy, with 
relative risks as high as 50 times that of the general population.[40] Interestingly, regardless 
of smoking history, incident lung cancers develop within the radiation-exposed lung 
parenchyma. HL survivors who develop lung cancer have a median survival of less than a 
year [41, 42], and recently have been shown to have a 60% less chance of survival than cases 
of stage-matched de novo lung cancer.[43] We continue to adamantly recommend smoking 
cessation (with the support of a smoking cessation clinic) to patients at the time of diagnosis 
given the interaction between cigarette smoking and therapy in augmenting the subsequent 
risk of lung cancer. Whether to screen at-risk patients with a history of HL, and if so, how 
best to do so, remain unanswered questions. National Comprehensive Cancer Network 
(NCCN) guidelines recommend annual chest imaging (either X-ray or CT scan) for all 
patients except those who were treated without alkylator therapy, mediastinal RT, and who 
have no other risk factors.[44] The recommendation of screening CT has been supported by 
cost modeling, showing it to be cost effective, particularly in smokers.[45] However, perhaps 
the greatest impetus, albeit indirect, for lung cancer screening in HL survivors comes from 
the National Lung Screening Trial.[46] This large randomized trial of non-cancer patients 
with strong smoking histories demonstrated that, with annual low-dose CT scans of the 
chest for three consecutive years, lung cancer-specific and overall survival could be 
improved. How best to extrapolate these findings to the HL survivor population is unclear, 
and the duration and intensity of screening will require further clarification, but an annual 
low-dose chest CT scan in at-risk survivors may well emerge as the de facto standard of 
care, and given the current body of data should be discussed with patients at risk. 
7. Breast cancer 
After 15 years of follow-up, women treated with mantle field radiation before the age of 20 
had a 40-fold increased risk of developing breast cancer compared to age-matched 
controls.[47] In a retrospective study of HL survivors treated with more modern radiation 
dose and delivery, doses as low as 4.0Gy to the breast were associated with a 3.2 fold cancer 
risk compared to women who were treated with lower doses of radiation. This risk 
increased to 8-fold for women treated with >40 Gy to the breast. Age at radiation dominates 
the risk assessment for second primary breast neoplasia; in one study, for instance, the 
actuarial risks of breast cancer for patients receiving mantle radiation by 25 years after 
treatment were 34%, 22%, and 3.5% for patients under age 20, age 20-30, and over age 30, 
respectively; radiation therapy to patients over the age of 30 appears to confer at most a 
minimal risk of subsequent breast cancer.[48] Concomitant use of alkylating agents or pelvic 
radiation can have protective effects against development of breast cancer, presumably due 
to the low-estrogen state induced by premature ovarian failure.[47, 49] The question of how 
best to monitor patients who have received treatment likely to increase breast cancer risk 
remains unanswered, and an area of active research.  
www.intechopen.com
 
Hodgkin's Lymphoma 260 
Guidelines for the screening of women for breast cancer continue to evolve, as do 
recommendations for screening high-risk patients, such as those with hereditary risk for 
breast cancer due to the inheritance of BRCA1 or BRCA2.[52] Unfortunately, many female 
HL survivors will also be at an increased risk for subsequent breast cancer, risk that is 
associated with exposure of breast tissue to ionizing radiation when contained in RT fields. 
For instance, women treated with mantle radiation under age 20 have a 40-fold increased 
risk of developing breast cancer compared to age matched controls at a median of 15 years 
follow-up.[21] Developmental age of breast tissue also strongly influences the risk of 
radiation induced carcinogenesis, as in patients who received mantle RT under the age of 20, 
age 20-30, and over 30 the risk of breast cancer was 34%, 22.3%, and 3.5% respectfully at 25 
years post treatment.[48] Given the many changes that have taken place in the delivery of 
RT in the treatment of HL (extended fields giving way to more limited involved fields; 
efforts at limiting dose; and improved simulation techniques, to name but three), it is hoped 
that risks of breast cancer following RT may be lower for patients treated in the current era. 
Nonetheless, recent data suggest that modern radiotherapy techniques may not in fact lead 
to reductions in second malignancy;[53] estimating risks of breast cancer will require 
ongoing reassessment so as to permit the most appropriate screening approach for 
individual patients given their individual risk profiles. Interestingly, concomitant use of 
alkylating agents or pelvic radiation can have protective effects against development of 
breast cancer, thought to be related to decreased estrogen production induced by treatment-
related ovarian suppression or premature ovarian failure.[54] If efforts at fertility 
preservation with administration of gonadotropin releasing hormone agonists prove 
successful, as may be the case in breast cancer therapy[55], it is possible this benefit may be 
either abrogated or nullified.[56] 
The optimal surveillance strategy for patients placed at increased risk for breast cancer by 
their HL therapy remains a subject of investigation, but standards of care are beginning to 
emerge. The National Comprehensive Cancer Network (NCCN) and the American Cancer 
Society (ACS) have recommended that, for those who received mediastinal radiotherapy 
before the age of 30, breast cancer surveillance should begin between eight and ten years 
following treatment.[50, 51] Mammography remains an important modality for breast 
cancer screening in this patient population, although the addition of an annual breast 
magnetic resonance imaging is reasonable for high-risk patients (particularly those with 
dense breasts on mammography, a finding that limits the sensitivity of mammography for 
early detection); the use of MRI in screening is extrapolated from a comparable risk group, 
women with BRCA1 mutation, in whom breast MRI has been validated as a useful element 
in screening programs.  
Many other types of solid tumor malignancies remain overrepresented in HL survivors. 
Papillary thyroid carcinoma is the most notable among them and is clearly associated with 
radiation therapy, although the risk of thyroid cancer decreases with doses above 30 Gy, 
consistent with increased cell kill of normal thyroid tissue.[58] Other radiation-associated 
cancers can be seen as well, including gastrointestinal carcinomata and soft tissue 
sarcomata, as well as a strong association with non-melanoma skin cancer, both basal and 
squamous cell histologies.[22] Given these risks, surveillance for second primary 
malignancy should take such risks into account, including modification of colorectal 
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screening for patients receiving infradiaphragmatic radiation, and special attention to skin 
examination in radiation fields.  
8. Cardiovascular toxicities 
While secondary malignancies remain the leading cause of mortality in long-term HL 
survivors, death due to cardiac causes places second and cardiovascular morbidity and 
mortality is far more common among HL survivors than among comparable untreated 
individuals. The specific cardiovascular toxicities for which HL survivors are at increased 
risk can include coronary artery disease (CAD), valvular heart disease, congestive heart 
failure (CHF), pericardial disease, electrical conduction abnormalities, and cerebrovascular 
disease.[59] 
9. Coronary artery disease 
HL survivors who receive radiotherapy to the mediastinum are at increased risk of early 
onset CAD. A British cohort of HL survivors was found to be 3.2 times more likely to suffer 
a myocardial infarction (MI) than population controls. [60] In Dutch HL survivors treated 
with mediastinal radiation, the 20-year cumulative risk of myocardial infraction was 
21.2%.[61] In a similar cohort Aleman et al. reported the risk of development of a myocardial 
infarction at 30 years post-radiation was 12.4%.[62] The selection of chemotherapy, 
including the use of anthracyclines, does not appear to definitively impact risks of CAD 
among survivors. Classical CAD risk factors (hypertension, diabetes, cigarette smoking, and 
hyperlipidemia) continue to play a role in promoting atherosclerosis in HL survivors, 
necessitating optimal medical management.[63] At present, there have only been two 
prospective studies of cardiac screening in HL survivors. Heidenreich et al. [64] reported an 
abnormal stress test (echocardiogram and/or radionucleotide myocardial perfusion scan) in 
21% of asymptomatic HL survivors fifty percent of those with an abnormal functional study 
demonstrated an obstructive lesion at the time of definitive coronary angiography. 
Furthermore, Kupeli et al. [65] use CT angiogram to detect subclinical CAD in survivors of 
childhood HL, and found a 6.8 times greater post-radiation HL survivors. CT angiography 
is felt to represent the non-invasive gold standard for detection of CAD, with sensitivity and 
specificity of 94% and 97%, respectfully, compared to fluoroscopic angiography.[66] 
Whether screening CT angiography is appropriate for adult HL survivors remains an open 
question, and indeed no standard of care yet exists for the surveillance for subclinical CAD 
in HL survivors. 
10. Valvular heart disease 
The risk of subsequent valvular heart disease is significantly increased among HL survivors 
treated with mediastinal RT, again believed due to direct toxic effects on the valve 
apparatus. Investigators have observed a seven- or eight-fold increase in the likelihood of 
experiencing significant valvular heart disease among irradiated survivors, risks that appear 
not to be mediated by chemotherapy agents or dosages.[62, 67] The aortic valve is the most 
commonly affected, and female gender appears to predispose to disease.[68] 
Echocardiographic surveillance to assess valvular competence is often included as an 
www.intechopen.com
 
Hodgkin's Lymphoma 262 
element of routine follow-up of HL survivors treated with mediastinal radiation, although 
as of yet no guidelines for adult survivors have been developed. 
11. Congestive heart failure 
Although the most common cause of congestive heart failure (CHF) in HL survivors is 
ischemic cardiomyopathy, significant concerns remain about the risk of late non-ischemic 
cardiomyopathy. While cumulative dose of anthracycline is associated with risks of CHF, 
currently the maximum cumulative dose of doxorubicin would not exceed 400 mg/m2 and 
typically would not exceed 300 mg/m2, the dose exposure from 6 cycles of ABVD, dose 
levels that would be expected to be associated with low risks of cardiomyopathy.[69, 70]  
Doxorubicin is not the only therapeutic agent for HL associated with CHF; It has long been 
recognized that mediastinal RT can predispose to CHF as well.[71] The impact of therapy on 
risk of subsequent CHF has been convincingly elucidated in patients treated as children for 
HL; data from the Childhood Cancer Survivor Study estimate a hazard ratio of 6.8 in HL 
survivors, with young age (<10y), female gender, higher doses of doxorubicin, and 
mediastinal RT all contributing to risk in multivariate modeling.[72] Subclinical LV 
dysfunction in survivors of childhood HL appears also to be common, although estimates of 
cumulative incidence are heterogeneous, ranging from 0 to 57% in 25 studies using 
traditional echocardiographic metrics (studies that were themselves heterogeneous in how 
subclinical LV dysfunction was defined).[73] Among patients treated for adult HL, long-
term survivors are at increased risk for developing CHF, with one set of estimates (among 
patients who largely did not receive anthracycline-based chemotherapy) of absolute excess 
risk ranging from 16-35 cases/10,000 person-years.[74] Furthermore, while mediastinal RT 
appears contributes to the increased cardiac morbidity in HL survivors treated as adults,[59] 
how this risk interacts with the risk attributable to anthracycline-based chemotherapy has 
not been well described. How best to monitor the LV function, or even to identify early or 
subclinical LV dysfunction, in HL survivors needs to be more rigorously investigated if 
evidence-based screening guidelines are to be developed. 
12. Pulmonary toxicity 
Beyond the risk of lung cancer (discussed above), therapy for HL has the potential of 
causing both acute and chronic lung disease. The three most common first-line regimens for 
HL – ABVD, Stanford V, and BEACOPP – all contain bleomycin, an agent with a well-
described association with pneumonitis. Baseline pulmonary function prior to initiation of 
bleomycin-containing therapy is standard, both to select a group of patients for whom such 
therapy is inappropriate as well as to establish baselines against which future tests (either 
routine surveillance in the absence of symptoms or testing to delineate the cause of dyspnea 
or cough) can be compared. Such complaints are common; as many as 30% of HL survivors 
will report the symptom of dyspnea during or after treatment.[19] Acute bleomycin 
pneumonitis is a serious, and potentially life-threatening condition, with mortality rates 
reported as high as 27%.[75] Patients who experience bleomycin pneumonitis, even when 
having survived and recovered from the acute episode, are more likely to report chronic 
fatigue and dyspnea than unaffected patients. Furthermore, when fields include pulmonary 
parenchyma, radiation therapy can also lead to acute pneumonitis or, later, pulmonary 
fibrosis, conditions that can compound the damage from bleomycin exposure. Given these 
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risks, many experts will elect to monitor PFT’s serially both during treatment as well as 
periodically among survivors. 
13. Endocrinopathies 
Endocrine systems are typically characterized by homeostatic balance supported by positive 
and negative feedback. The organs involved in such systems may be susceptible to damage 
or disruption from cytotoxic chemotherapy or ionizing radiation, and indeed survivors of 
HL are at risk for dysfunction of several hormonal systems. Therapy for HL can be toxic to 
the thyroid and the gonads, resulting in hypothyroidism and compromised fertility, 
respectively. 
14. Thyroid disease 
Hypothyroidism is a potential long-term consequence of radiotherapy involving the thyroid 
bed. Unlike papillary thyroid cancer, an uncommon late sequela of thyroid irradiation, 
hypothyroidism is seen in at least half of HL survivors who are more then 10 years from 
treatment cancer having undergone RT involving the thyroid.[76] Risk factors associated 
with higher rates of hypothyroidism in HL survivors in addition to dose and field of 
radiation include female gender, treatment with combined-modality therapy, and duration 
of time since radiation. [77] There is no consensus on the optimal frequency of thyroid 
stimulating hormone screening or the value at which to initiate thyroid hormone 
replacement in the absence of symptomatic hypothyroidism, but treatment with thyroid 
hormone replacement is routine and effective at minimizing the impact of hypothyroidism.  
15. Gonadal dysfunction   
Given the epidemiology of the disease, survivors of HL are often young, functional, and 
potentially fertile.[78] Unfortunately, treatments for HL may lead to temporary infertility, 
primary gonadal failure (azoospermia or primary ovarian failure), or subfertility 
(dysspermatogenesis or early onset of menopause). Given high cure rates among patients 
who will often go on to want to have children, investigators have sought to understand the 
impact of treatment on fertility, as well as how best to safeguard fertility prospectively. 
While a full discussion of fertility preservation is beyond the scope of this chapter, choice of 
chemotherapeutic agents, total dose of chemotherapy, radiation field and dose, and age at 
treatment are influence the outcomes with regards to fertility. The selection of therapy, 
including alkylating chemotherapy and pelvic radiation, has the potential to impact fertility 
in both men and women.[79, 80]  In male patients, semen cryopreservation when possible 
should be encouraged before commencing chemotherapy so as to preserve fertility should 
azoospermia result from treatment, although some patients will be incapable of banking 
adequate semen, presumed to be due to the cytokine milieu caused by the underlying 
lymphoma. While ABVD chemotherapy results in temporary azoospermia in approximately 
one third of patients, permanent azoospermia is rare. This stands in contrast to more 
intensified regimen using bleomycin, etoposide, doxorubicin, cyclophosphamide, 
vincristine, procarbazine, and prednisone (baseline or escalated BEACOPP), which typically 
leads to durable azoospermia.[81]  
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In female patients, risk of infertility or subfertility is thought to be influenced by delivered 
therapy, intensity of therapy (number of cycles), and perhaps age at treatment. The leading 
cause of infertility is related to premature ovarian failure as a result of chemotherapy, 
radiation or combined modality therapy.[82] While egg preservation is commonly discussed 
at the time of consultation prior to proceeding to definitive treatment, not infrequently the 
pace of the disease, financial constraints, or patient choice are barriers to fertility 
preservation for women. For those who have been treated and subsequently attempt natural 
pregnancy, the data support optimism regarding likelihood of conception. In females who 
had received ABVD without pelvic radiation therapy and had no evidence of relapsed at 
three years were surveyed on their experience on fertility. Hodgson et al. found that of those 
that attempted to become pregnant 70% were successful with a median time to pregnancy of 
2 months.[83] Interestingly, in this report the age at diagnosis or the number of cycles of 
chemotherapy did not demonstrate an increase risk of subfertility compared to controls. 
Further data is emerging with patients with aggressive disease by prognostic modeling 
warranting initial intense treatment with BEACOPP, a regimen felt by most to be 
significantly more pituitary-gonadal axis. Dann et al. [84] reported that in patients younger 
than 40 with locally unfavorable or advanced HL whom underwent up to 4 cycles of initial 
BEACOPP therapy an astounding 94% of had preserved cyclic ovarian function. 
Furthermore, they reported numerous successful pregnancies in this cohort up to 7 years 
after commencement of BEACOPP. While this data is encouraging egg preservation or other 
options to facilitate preservation of fertility in an imperative part of the treatment plan. 
Recent research into ovarian suppression with gonadotropin releasing hormone agonists 
prior to initiation of chemotherapy has shown promise, with a recent large randomized 
clinical trial in women with breast cancer showing a statistically significant decrease in rates 
of amenorrhea 12 months after completion of adjuvant therapy from 26% to 9%.[55] More 
definitive efforts at preservation of female fertility include cryopreservation of fertilized 
embryos or, more recently, unfertilized ova elective oophorectomy with cryopreservation 
and re-implantation after therapy; and transposition of the ovary outside of pelvic 
radiotherapy fields.[56] For the survivor of HL, however, pre-treatment fertility 
preservation is something that was, or was not, done, and there are no established 
interventions to promote or restore fertility in the post-treatment setting. Recently, however, 
investigations into the use of anti-Müllerian hormone (AMH) levels to predict both the 
ability to conceive as well as the likelihood of early menopause in cancer survivors, have 
offered future promise for a more individualized assessment of fertility prospects and 
guidance regarding family planning.[85] 
16. Health related quality of life 
In addition to the medical morbidities that survivors of Hodgkin lymphoma may experience 
due to their disease and its treatment, there exist significant risks as well of impaired  
quality of life, with fatigue, anxiety and depression, and impaired vocational success having 
been well described among HL survivors. An understanding of the global well-being of 
survivors requires incorporation of psychosocial support into the delivered multi-
disciplinary care.  
Health related quality of life (HRQOL) encompasses a patient’s perception of physical, 
psychological, and social well-being. In a 10-year follow-up of survivors of early stage HL in 
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Europe, women tended to have a lower HRQOL and higher symptoms scores than did men. 
Regardless of gender, younger age was associated with higher functioning and lower 
symptom severity score, and emotional suffering was generally reported to be more severe 
than physical symptoms.[86] Of note, results in this study did not demonstrate a 
relationship between type of treatment and HRQOL outcomes. In a study out of the 
Southwest Oncology Group in the United States, a comparison of HRQOL in patients 
treated with either EFRT or CMT found persistent fatigue reported by survivors of each 
treatment modality, but again without differences according to treatment.[87] Effects seem 
to wane as length of time post-treatment increases; HL survivor 10 years from treatment 
continue to report lower general health scores, but many specific QOL domains no longer 
differ between treated patients and age-matched controls.[88, 89]  
17. Chronic fatigue 
A common theme among investigations into the quality of life of survivors of HL has been 
the impact of persistent and pervasive fatigue.[86, 87, 90] Chronic fatigue is three times 
more likely in HL survivors than in age matched controls, and is less likely to be associated 
with poor mental health than in untreated patients who experience chronic fatigue.[89, 91]  
Retrospective studies have attempted to characterize pre-existing risk factors that can 
predict post-treatment chronic fatigue, and reports have implicated B symptoms at 
diagnosis, social isolation, and presence of treatment-related pulmonary toxicity.[91, 92]  
The underlying cause of chronic fatigue in HL survivors remains incompletely understood, 
although ongoing research suggests a link between chronic fatigue in cancer survivors and 
inappropriate elevation of proinflammatory cytokines.[93-95] At this time, however, the 
interventions that have been shown to impact chronic fatigue in HL survivors the most 
favorably are cognitive behavioral therapy and structured aerobic exercise.[96-98] 
18. Psychiatric morbidity 
An extensive literature exists describing the frequency and severity of psychological and 
psychiatric morbidity among cancer survivors in general, and recent investigations have 
attempted to characterize the impact on mental health resulting from diagnosis and 
treatment of Single-institution data has found that, at a median follow-up of 21 years, 17% of 
HL survivors reported having being diagnosed with major depression, and of these 90% had 
been prescribed one or more anti-depressant medications; an additional 12% denied 
depression but reported significant anxiety in the post-treatment period.[99] In an analysis 
of survivors of HL in Norway, both anxiety and depression were overrepresented, and risk 
of mental illness was associated with lower economic status, having received combined-
modality therapy (as opposed to radiation alone), and having had a prior history of a 
psychiatric diagnosis.[100] It appears the peak risk of depression is at 2 years post diagnosis 
with a gradual decline thereafter, but the risk of depression, anxiety, and post-traumatic 
stress disorder can be lifelong and requires collaboration with mental health professionals in 
the delivery of multi-disciplinary care to HL survivors.[101-103] 
19. Occupational outcomes 
For many patients diagnosed with HL, symptoms from the illness, time for testing and 
treatment, and the resultant acute and chronic toxicities from therapy can significantly 
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disrupt careers and limit employment opportunities post-treatment. Several factors 
including limit the ability to continue working or return to work include disease 
characteristics at the time of diagnosis (site, stage, treatment, and disease response), patient 
characteristics (age, gender, comorbidity, socioeconomic status), and work-related factors 
(physical workload, stress, and social support).[104] Younger patients with good disease 
control and higher educational attainment are more likely to return to pre-diagnosis 
socioeconomic stature.[102, 104]  Among HL survivors 20 years from treatment, 18% 
reported that treatment for their HL interfered with their career 11% that it prevented 
subsequent full-time employment, and 9% that they were incapable even of routinely 
completing household chores.[99] While employment status in the United States is closely 
linked to both health and life insurance, HL survivors often suffer a negative impact on their 
insurance status, even after prolonged remissions.[105] Collectively, these challenges may 
ultimately disrupt the family support network, but interestingly, despite these challenges 
HL survivors who were married at the time of diagnosis do not appear to experience higher 
divorce rates than the general population in either the United States nor the Netherlands, to 
name but two examples.[102, 106] 
20. Future research in the care of survivors 
As clinical research in the management of HL continues to develop, with reduction in 
radiation fields, further limitation of chemotherapy dosages, response-adapted therapy, and 
possibly eliminating or replacing the most offensive agents in current multi-agent 
chemotherapeutic programs, opportunities for understanding and discovery in the field of 
HL survivorship will endure. With the recent FDA approval of brentuximab vedotin in the 
treatment of relapsed CD30+ HL – the first drug specifically approved for HL – this agent is 
now be tested earlier in the course of therapy, potentially replacing bleomycin in 
ABVD.[107] Many additional classes of agents have shown promise in HL, including 
immunomodulatory agents, histone deacetylase inhibitors, inhibitors of the mammalian 
target of rapamycin (mTOR), and phosphoinositide-3 kinase (PI3K) inhibitors, to name but 
four. In this era of rapidly expanding armamentarium of therapeutics, it is imperative that 
prospective protocols employ thoughtful correlative studies that ask and are powered to 
answer not only the question regarding acute toxicity, but also late medical morbidity and 
impact upon quality of life. Also sorely needed are guidelines to aide physicians in 
monitoring their patients for the myriad late effects associated with therapy – and the data 
to inform such guidelines. And as HL survival continues to improve (and as oncologists 
become an increasingly limited resource), models of efficient and effective multi-
disciplinary care for survivors of HL need to be developed, tested, and propagated.[108]  
21. Conclusion  
Survivors of Hodgkin lymphoma represent a unique group of patients who, despite having 
been cured of an aggressive and life-threatening malignancy, continue to suffer from late 
medical and psychosocial morbidities associated with their diagnosis, treatment, and the 
sequelae thereof. Risks of second primary malignancy, cardiovascular disease, pulmonary 
disease, and endocrine dysfunction are influenced by patient characteristics such as age and 
gender, and treatment characteristics, such as selected chemotherapy and the inclusion, 
dose, and field of radiotherapy. Psychosocial challenges appear to be less treatment-
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dependent, but represent no less of a challenge to well-being among survivors. As 
treatments continue to evolve, and as our understanding of these risks – who is at risk, how 
best to identify or screen for them, and even how best to prevent them – evolves as well, the 
need will only become greater for evidence-based management guidelines. With the 
appropriate tools, engaged physicians can become all the more capable of promoting and 
preserving health among patients with, and survivors of, Hodgkin lymphoma.  
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